Evidence map›Paper›PMID 33390805›Full record

ArticleInternational journal of medical sciences2021

Polymeric immunoglobulin receptor (PIGR) exerts oncogenic functions via activating ribosome pathway in hepatocellular carcinoma.

Yuan Zhang, Jijie Zhang, Xiaorong Chen, Zongguo Yang

Open access · goldAbstract read
In one paragraph

Article in International journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Hepatocellular Carcinoma: A Comprehensive Review.Diseases (Basel, Switzerland) · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Polymeric immunoglobulin receptor (pIgR) in cancer.Journal of cancer research and clinical oncology · 2023
    Review
  15. Article
  16. EMT and Inflammation: Crossroads in HCC.Journal of gastrointestinal cancer · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yuan ZhangDepartment of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Jijie ZhangDepartment of Oncology, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Jiangsu 212300, China.
Xiaorong ChenDepartment of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Zongguo YangDepartment of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Shanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorCarcinogenesisCarcinoma, HepatocellularCell Line, TumorDatasets as TopicDisease-Free SurvivalDisease ProgressionGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansLiverLiver NeoplasmsNeoplasm Recurrence, LocalReceptors, Polymeric ImmunoglobulinRibosomal ProteinsRibosomesBiomarkers, TumorReceptors, Polymeric ImmunoglobulinRibosomal Proteinsdisease-free survivalhepatocellular carcinomapolymeric immunoglobulin receptorrecurrenceribosome

Identifiers

PMID33390805
PMCPMC7757154
OpenAlexW3111324986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.